Search Videos and More


New International Partnership to Accelerate Search for Cancer Cures News

New International Partnership to Accelerate Search for Cancer Cures

Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment News

Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment

In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.
Multiple Myeloma Research: Risks, Benefits of Stem Cell Transplant Video

Multiple Myeloma Research: Risks, Benefits of Stem Cell Transplant

Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson Video

ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson

Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: a study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
New Protein Complex Structure Reveals Possible Ways To Target Key Cancer Pathway News

New Protein Complex Structure Reveals Possible Ways To Target Key Cancer Pathway

Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma News

Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma

Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Scientists Identify Potential Target in Ewing Sarcoma Cells News

Scientists Identify Potential Target in Ewing Sarcoma Cells

Investigators led by Dana-Farber Cancer Institute’s Kimberly Stegmaier, MD, have discovered that knocking out a protein regulator in Ewing sarcoma cells causes the tumor cells to die from an overdose of a cancer-promoting protein.
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia News

Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia

Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.
Venetoclax Shown to Benefit Patients with Waldenström Macroglobulinemia, Including Some Who Relapsed After Previous Therapy News

Venetoclax Shown to Benefit Patients with Waldenström Macroglobulinemia, Including Some Who Relapsed After Previous Therapy

A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.
Mantle Cell Lymphoma Clinical Trial News

Mantle Cell Lymphoma Clinical Trial

Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study Video

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study

Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.